Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study
Axel S. Merseburger, Gerhardt Attard, Lennart Åström, В. Б. Матвеев, Sergio Bracarda, Adil Esen, Susan Feyerabend, Elżbieta Senkus, Marta López-Brea Piqueras, Gunther Boysen, Georgia Gourgioti, Karla Martins, Simon Chowdhury
Topics & Concepts
MedicineEnzalutamideDocetaxelProstate cancerAndrogen deprivation therapyPlaceboInternal medicineProstate-specific antigenUrologyOncologyCancerAndrogen receptorPathologyAlternative medicineProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentBone health and treatments